Frontier Biotechnologies Inc. Class ASSE: 688221

Announcement on Voluntary Disclosure on Obtaining Notice of Approval for Phase II Clinical Trials of Aikening's New Maintenance Treatment Indications

· Issued by Frontier Biotechnologies Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure on Obtaining Notice of Approval for Phase II Clinical Trials of Aikening's New Maintenance Treatment Indications

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis